Takeda Pharmaceutical Co ADR (TAK) is overvalued and Teva- Pharmaceutical Industries Ltd (TEVA) is overvalued.
Both trade above our estimate of their intrinsic value. TAK is the closer of the two: -86%, against -92% for TEVA.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.6% (average of 2 methods) values the shares at $10.20; the price of $18.95 is 86% above that value, and 77% of that value comes from beyond year five.
Leak Score 0/100 on 2 of 12 signals
Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $20.57; the price of $39.52 is 92% above that value, and 77% of that value comes from beyond year five.
Leak Score 0/100 on 3 of 12 signals
| Metric | TAK | TEVA |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $18.95 | $39.52 |
| Intrinsic value | $10.20 | $20.57 |
| Margin of safety | -86% | -92% |
| Leak Score | 0/100 (2/12) | 0/100 (3/12) |
| Market cap | $60.3B | $46.1B |
| Revenue growth, 5 years | -0.2% | 0.8% |
| Operating margin | 15.3% | 18.8% |
| Net margin | -3.5% | 4.1% |
| Return on equity | -2.2% | 9.7% |
| Debt to equity | 0.65 | 2.18 |
| P/E | — | 65.9x |
| Forward P/E | 30.2x | 12.9x |
| P/B | 1.3x | 5.9x |
| Dividend yield | 3.4% | — |